Navigation Links
Nuvo announces proposed amendments to outstanding convertible debentures
Date:8/1/2008

MISSISSAUGA, ON, Aug. 1 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that it is proposing to amend the terms of its convertible, unsecured debentures (the "Debentures"), of which $4.136 million principal amount are outstanding. The Debentures were issued in November, 2004, pay interest at a rate of 5.0% per annum, currently mature in November, 2009 and are currently convertible into common shares of Nuvo at a price of $0.30 per share (except for certain Debentures held by directors and officers of Nuvo, which are currently convertible at a price of $0.39 per share).

The board of directors of Nuvo has determined that it would be prudent, and in the best interests of Nuvo, to extend the maturity date of the Debentures. As such, Nuvo is seeking the approval of the holders of the Debentures to extend the maturity date for one year to November 16, 2010. In consideration for the holders of the Debentures agreeing to such extension, Nuvo will reduce the conversion price of the Debentures to the current five-day volume weighted average trading price of the common shares, being $0.138. Nuvo intends to seek the approval of the holders of the Debentures over the next few weeks by way of a written resolution, which, to be effective, must be signed by holders of two-thirds of the outstanding principal amount of the Debentures.

"These debentures are potentially problematic in that they mature and would have to be repaid, if not converted, soon after the date by which we expect to receive the U.S. FDA's response to our application for Pennsaid approval, which we expect to submit to the FDA in early 2009," stated Jim Moulds, Nuvo's Chief Financial Officer. "Our focus over the past several months has been to extend our financial runway as far as possible beyond the expected response date by exploring means of raising and conserving cash. The proposed amendments to the convertible debentures, if accepted by holders of two-thirds of the outstanding principal amount, represent the removal of a potentially large cash outlay in November, 2009."

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego California. For more information, please visit http://www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Company's Annual Information Form for the year ended December 31, 2007. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at http://www.sedar.com.


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anpath Group, Inc. Announces Appointments of David V. Gilroy and Paul A. Boyer to Board of Directors
2. Weight Watchers Announces Second Quarter 2008 Results
3. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
4. Smart Balance Announces Marketing Organization Appointment
5. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
6. Regence Foundation Announces Three Grants Totaling $195,000
7. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
8. VA Announces New Nursing Academy Sites
9. AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio
10. Nuvo announces second quarter 2008 financial results
11. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking into ... depicts every parent’s worst nightmare, when her three children were violently taken from her. ... my divorce,” James said. “After the death of my children, I continued to journal. ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of unique liquid food supplements, announced its popular products are now available for ... , ALP Nutrition® prioritizes the use of premium natural ingredients in making all ...
(Date:4/24/2017)... Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... chai teas, announced its products are now available for purchase on RevNutrition.com, a popular ... form of tea first produced and popularized in ancient India and Siam. It spread ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... healthcare compliance and credentialing solutions, today announced that Kyle Allain has joined the ... Cactus Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to 78,000 ... 25,000 of them will be malignant.(1) As research into precision medicine continues, both ... model in the diagnosis and treatment of brain tumors. Healthcare facilities that are ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 24, 2017 Solentim, the developer of ... addition of a major new product line called ... The VIPS has been developed for automatically seeding ... as part of the process to generate clonally-derived ... and more reliable solution when compared to traditional ...
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
Breaking Medicine Technology: